Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective. (April 2022)

• Record Type: Journal Article
• Authors: Dela-Pena, Jacqueline C.; King, Madeleine A.; Brown, Julia; Nachar, Victoria R.
• Is Part Of: Journal of oncology pharmacy practice. Volume 28:Number 3(2022)
• Page Start: 646
• Page End: 663
• Publication Date: 2022-04
• Subjects: Sickle cell disease -- hydroxyurea -- L-glutamine -- crizanlizumab -- voxelotor; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/10781552211072468
• Languages: English
• ISSNs: 1078-1552

Abstract

Patients with sickle cell disease (SCD) experience significant disease-related morbidity including multiorgan damage, chronic anemia, and debilitating pain crises. While hydroxyurea has been the primary disease modifying modality in SCD, novel therapies with unique mechanism of action have recently been approved. This review article examines the evidence surrounding the available SCD therapies to guide pharmacists on potential treatment selection and management strategies for patients with SCD. A systematic search of online databases was performed to identify literature on the management of SCD. While the newly approved novel agents have demonstrated clinical benefit it remains unclear how these agents fit into the treatment paradigm. Pharmacists should be aware of the data supporting the use of these novel agents to optimize use on a patient-specific basis.